ABB (Japan)

Recent papers from ABB (Japan)

1. Characteristics and Hospitalization Details of Patients with Advanced Parkinson’s Disease Receiving Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa: Real-World First-Year Descriptive Study from JapanNeurology and Therapy · 2026
2. Economic Burden and Treatment Patterns Among Patients Diagnosed With Vitiligo in Japan: An Observational Retrospective Cohort StudyThe Journal of Dermatology · 2026
3. Immunogenicity and safety of recombinant zoster vaccine in Japanese patients with RA receiving upadacitinib: the end Zoster-J studyScientific Reports · 2026
4. Real‐World Maintenance of Remission in Atopic Dermatitis Patients With Upadacitinib: A Multicenter Retrospective Study in Japan ( ROADMAP Study)The Journal of Dermatology · 2026
5. A phase 2 randomized study comparing telisotuzumab adizutecan monotherapy with standard of care in patients with post-adjuvant circulating tumor DNA–positive colorectal cancer.Journal of Clinical Oncology · 2026
6. Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational StudyDermatology and Therapy · 2026
7. Safety and Effectiveness of Glecaprevir/Pibrentasvir in Children and Adolescents With Chronic Hepatitis C: Reports From All‐Case Post‐Marketing Surveillance in JapanHepatology Research · 2026
8. Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: long-term efficacy and safety through 5 years in the SELECT-EARLY studyModern Rheumatology · 2026
9. A phase 2 randomized study comparing telisotuzumab adizutecan monotherapy with standard of care in patients with post-adjuvant circulating tumor DNA-positive colorectal cancer.Journal of Clinical Oncology · 2026
10. Clinical significance of c-Met expression in patients with advanced gastroesophageal adenocarcinoma.Journal of Clinical Oncology · 2026
11. RO4938581, a GABAA-α5 negative allosteric modulator rescued behavioral and EEG phenotypes of a mouse model of Dup15q syndromeMolecular Psychiatry · 2026
12. Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in JapanInternational Journal of Hematology · 2025
13. Comparative effectiveness of atogepant and rimegepant for migraine prevention in Japanese patients: an anchored matching-adjusted indirect comparisonExpert Review of Neurotherapeutics · 2025
14. Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trialsArthritis Research & Therapy · 2025
15. Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 studyInternational Journal of Hematology · 2025
16. Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 studyInternational Journal of Hematology · 2025
17. Real-world outcomes of venetoclax and azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia (VENUS study)International Journal of Hematology · 2025
18. Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trialRMD Open · 2025
19. Atogepant for the preventive treatment of episodic migraine in Japanese participants: A phase 2/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE)Cephalalgia · 2025
20. Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphomaInternational Journal of Clinical Oncology · 2025